Significant differences exist when contrasting cancer management approaches in the US and Europe. The American model, generally characterized by private insurance and a emphasis on innovation, often leads to rapid introduction of new therapies, albeit at a significantly higher cost. In contrast, Continental systems frequently lean on state funding